Chiral perturbation theory

The main elements and methods of chiral perturbation theory, the effective field theory of the Standard Model below the scale of spontaneous chiral symmetry breaking, are summarized. Applications to the interactions of mesons and baryons at low energies are reviewed, with special emphasis on developments of the last three years. Among the topics covered are the strong, electromagnetic and semileptonic weak interactions of mesons at and beyond next--to--leading order in the chiral expansion, nonleptonic weak interactions of mesons, virtual photon corrections and the meson--baryon system. The discussion is limited to processes at zero temperature, for infinite volume and with at most one baryon.Comment: 84 pages, Latex, 11 PostScript figures (in separate file) embedded with epsfig.sty, complete ps file (compressed, uuencoded, 0.6 MB) available via email on request; to appear in Progr. Part. Nucl. Phys., vol. 3

Oral tolerance inhibits pulmonary eosinophilia in a cockroach allergen induced model of asthma: a randomized laboratory study

<p>Abstract</p> <p>Background</p> <p>Antigen desensitization through oral tolerance is becoming an increasingly attractive treatment option for allergic diseases. However, the mechanism(s) by which tolerization is achieved remain poorly defined. In this study we endeavored to induce oral tolerance to cockroach allergen (CRA: a complex mixture of insect components) in order to ameliorate asthma-like, allergic pulmonary inflammation.</p> <p>Methods</p> <p>We compared the pulmonary inflammation of mice which had received four CRA feedings prior to intratracheal allergen sensitization and challenge to mice fed PBS on the same time course. Respiratory parameters were assessed by whole body unrestrained plethysmography and mechanical ventilation with forced oscillation. Bronchoalveolar lavage fluid (BAL) and lung homogenate (LH) were assessed for cytokines and chemokines by ELISA. BAL inflammatory cells were also collected and examined by light microscopy.</p> <p>Results</p> <p>CRA feeding prior to allergen sensitization and challenge led to a significant improvement in respiratory health. Airways hyperreactivity measured indirectly via enhanced pause (Penh) was meaningfully reduced in the CRA-fed mice compared to the PBS fed mice (2.3 ± 0.4 vs 3.9 ± 0.6; p = 0.03). Directly measured airways resistance confirmed this trend when comparing the CRA-fed to the PBS-fed animals (2.97 ± 0.98 vs 4.95 ± 1.41). This effect was not due to reduced traditional inflammatory cell chemotactic factors, Th2 or other cytokines and chemokines. The mechanism of improved respiratory health in the tolerized mice was due to significantly reduced eosinophil numbers in the bronchoalveolar lavage fluid (43300 ± 11445 vs 158786 ± 38908; p = 0.007) and eosinophil specific peroxidase activity in the lung homogenate (0.59 ± 0.13 vs 1.19 ± 0.19; p = 0.017). The decreased eosinophilia was likely the result of increased IL-10 in the lung homogenate of the tolerized mice (6320 ± 354 ng/mL vs 5190 ± 404 ng/mL, p = 0.02).</p> <p>Conclusion</p> <p>Our results show that oral tolerization to CRA can improve the respiratory health of experimental mice in a CRA-induced model of asthma-like pulmonary inflammation by reducing pulmonary eosinophilia.</p

Recent Developments in Chiral Perturbation Theory

I review recent developments in chiral perturbation theory (CHPT) which is the effective field theory of the standard model below the chiral symmetry breaking scale. The effective chiral Lagrangian formulated in terms of the pseudoscalar Goldstone bosons ($\pi, \, K, \, \eta$) is briefly discussed. It is shown how one can gain insight into the ratios of the light quark masses and to what extent these statements are model--independent. A few selected topics concerning the dynamics and interactions of the Goldstone bosons are considered. These are $\pi \pi$ and $\pi K$ scattering, some non--leptonic kaon decays and the problem of strong pionic final state interactions. CHPT also allows to make precise statements about the temperature dependence of QCD Green functions and the finite size effects related to the propagation of the (almost) massless pseudoscalar mesons. A central topic is the inclusion of matter fields, baryon CHPT. The relativistic and the heavy fermion formulation of coupling the baryons to the Goldstone fields are discussed. As applications, photo--nucleon processes, the $\pi N$ $\Sigma$--term and non--leptonic hyperon decays are presented. Implications of the spontaneously broken chiral symmetry on the nuclear forces and meson exchange currents are also described. Finally, the use of effective field theory methods in the strongly coupled Higgs sector and in the calculation of oblique electroweak corrections is touched upon.Comment: TeX, 110 pages, 15 figures available upon request, BUTP-93/0

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

To develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce

Company-level family policies: Who has access to it and what are some of its outcomes

Despite the increase in number of studies that examine the cross-national variation in the policy configuration that allow a better work-family integration, very few look beyond the national levels. It is also crucial to examine occupational level welfare since companies may restrict or expand the existing national level regulations, defining the “final availability” workers actual have towards various arrangements. In addition, companies may provide various additional arrangements through occupational policies which are not set out in the national level agreements that are crucial in addressing reconciliation needs of workers. This chapter examines what types of arrangements are provided at the company level to address work-family demands of workers. It further provides a synthesis of studies that examine both national level contexts and individual level characteristics that explain who gets access to company level family-friendly policies, which is linked to the possible outcomes of these policies

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)